Literature DB >> 21380538

Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of "lesion activity".

Daniel Pauleikhoff, Bernd Kirchhof.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21380538     DOI： 10.1007/s00417-011-1639-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  4 in total

1.  Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.

Authors:  Adnan Tufail; Praveen J Patel; Catherine Egan; Philip Hykin; Lyndon da Cruz; Zdenek Gregor; Jonathan Dowler; Mohammed A Majid; Clare Bailey; Quresh Mohamed; Robert Johnston; Catey Bunce; Wen Xing
Journal:  BMJ       Date:  2010-06-09

2.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

3.  The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model.

Authors:  Frank G Holz; Jean-François Korobelnik; Paolo Lanzetta; Paul Mitchell; Ursula Schmidt-Erfurth; Sebastian Wolf; Sabri Markabi; Heinz Schmidli; Andreas Weichselberger
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-06       Impact factor: 4.799

4.  Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.

Authors:  David M Brown; Mark Michels; Peter K Kaiser; Jeffrey S Heier; Judy P Sy; Tsontcho Ianchulev
Journal:  Ophthalmology       Date:  2009-01       Impact factor: 12.079
  4 in total
  6 in total

1.  Therapeutic efficacy of bevacizumab for age-related macular degeneration: what are the implications of CATT for routine management?

Authors:  Focke Ziemssen; Bianka Sobolewska
Journal:  Drugs Aging       Date:  2011-11-01       Impact factor: 3.923

Review 2.  Defining response to anti-VEGF therapies in neovascular AMD.

Authors:  W M Amoaku; U Chakravarthy; R Gale; M Gavin; F Ghanchi; J Gibson; S Harding; R L Johnston; S P Kelly; S Kelly; A Lotery; S Mahmood; G Menon; S Sivaprasad; J Talks; A Tufail; Y Yang
Journal:  Eye (Lond)       Date:  2015-04-17       Impact factor: 3.775

3.  FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity.

Authors:  Jordi Monés; Marc Biarnés; Fabio Trindade; Ricardo Casaroli-Marano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-04-15       Impact factor: 3.117

Review 4.  Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations.

Authors:  Laurent Kodjikian; Mariacristina Parravano; Andreas Clemens; Rosa Dolz-Marco; Frank G Holz; Marion R Munk; Massimo Nicolò; Federico Ricci; Rufino Silva; S James Talks; Rohini Kumar Verma; Javier Zarranz-Ventura; Sandrine A Zweifel
Journal:  Eye (Lond)       Date:  2021-04-01       Impact factor: 3.775

5.  Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study.

Authors:  Jean-Marie Rakic; Anita Leys; Heidi Brié; Kris Denhaerynck; Christy Pacheco; Stefaan Vancayzeele; Christine Hermans; Karen Macdonald; Ivo Abraham
Journal:  Clin Ophthalmol       Date:  2013-09-19

Review 6.  Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD.

Authors:  Miltiadis K Tsilimbaris; Maria I López-Gálvez; Roberto Gallego-Pinazo; Philippe Margaron; George N Lambrou
Journal:  J Ophthalmol       Date:  2016-03-17       Impact factor: 1.909
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.